独立意见 根据《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号-主板上市公司规范运作》以及《公 司章程》、《独立董事工作制度》等有关规定，我们作为重药控股股份有限公司（以 下简称"公司"）的独立董事，认真审阅了公司第八届董事会第十七次会议的会 议材料，并参加了会议，现就公司本次会议审议的《关于控股子公司调整担保额 度的议案》发表独立意见如下： 重药控股股份有限公司独立董事 关于公司第八届董事会第十七次会议相关事项的 本次调整为下属公司提供担保的额度是根据其业务实际开展情况和资金需 求做出的合理调整，财务风险可控，不会对公司的正常运作和业务发展造成不利 影响，不存在损害公司及股东尤其是中小股东利益的情形。该担保事项符合相关 规定，决策程序合法、有效；同意本次担保事项，并提交股东大会审议。 独立董事：章新蓉、龚涛、李豫湘、赵建新 2023 年 9 月 27 日 ...

证券代码：000950 证券简称：重药控股 公告编号：2023-087 重药控股股份有限公司 关于重庆医药（集团）股份有限公司实施 重药控股股份有限公司（以下简称"公司"、"重药控股"）于 2023 年 6 月 9 日召开了第八届董事会第十五次会议及第八届监事会第十七次会议，审议通过了 《关于重庆医药（集团）股份有限公司实施市场化债转股的议案》。公司下属控 股子公司重庆医药（集团）股份有限公司（以下简称"重药股份"）拟公开引进投 资人增资，增资总规模不超过 20 亿元，增资资金用于偿还重药股份的带息负债。 具体情况详见公司于 2023 年 6 月 10 日披露的《关于重庆医药（集团）股份有限 公司实施市场化债转股的公告》（公告编号：2023-060）。 二、本次进展情况 截至本公告披露日，重药股份已完成公开引进投资人，由工银金融资产投资 有限公司、中银金融资产投资有限公司、建信金融资产投资有限公司共同作为投 资人以市场化债转股方式对重药股份增资 20 亿元，其中工银金融资产投资有限 公司增资 10 亿元、中银金融资产投资有限公司增资 6 亿元、建信金融资产投资 有限公司增资 4 亿元。增资后，重药股份的注册资 ...

完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第八届董事会第十七次会议于 2023年9月27日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2023年9月20日以电子邮件和电话通知方式发出。会议应出席董事11人，实际出 席会议的董事11人。会议由公司董事长袁泉主持。本次会议的召开符合《公司法》、 《公司章程》的有关规定。 二、董事会会议审议情况 证券代码：000950 证券简称：重药控股 公告编号：2023-083 重药控股股份有限公司 第八届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 三、备查文件 公司第八届董事会第十七次会议决议 特此公告 重药控股股份有限公司董事会 （一）审议通过《关于控股子公司调整担保额度的议案》 具体内容详见同日披露的《关于控股子公司调整担保额度的公告》。 公司独立董事已对该议案发表了同意的独立意见。 表决结果：同意11票，反对0票，弃权0票。 本议案尚需提交股东大会审议。 （二）审议通过《关于召开 2023 年第三次临时股东大会的议案》 具体内容详见同日披露的《关于召开 ...

重药控股股份有限公司 关于召开 2023 年第三次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 重药控股股份有限公司（以下简称"公司"）第八届董事会第十七次会议决 定召开公司 2023 年第三次临时股东大会，详见公司 2023 年 9 月 28 日披露的第 八届董事会第十七次会议决议公告（公告编号：2023-083）。现将有关事项公告 如下： 一、召开会议的基本情况 证券代码：000950 证券简称：重药控股 公告编号:2023-086 1、股东大会届次：2023 年第三次临时股东大会 2、股东大会召集人：重药控股股份有限公司董事会 3、会议召开的合法性和合规性：公司第八届董事会第十七次会议审议通过 了《关于召开 2023 年第三次临时股东大会的议案》，本次股东大会会议召开符 合有关法律、行政法规、部门规章、规范性文件和公司章程的有关规定。 4、会议召开的日期和时间： （1）现场会议召开时间：2023 年 10 月 13 日（星期五）14:30 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2023 年 10 月 ...

Group 1: Company Overview and Business Segmentation - The main business of Chongqing Pharmaceutical Holdings is drug distribution, accounting for approximately 60-70 billion [1] - Retail, traditional Chinese medicine, and emerging businesses contribute around 20 billion and 10 billion respectively [1] Group 2: Strategic Development and Mergers - The company aims to establish or acquire enterprises in over 300 prefecture-level cities across the country, in line with its "Three Hundred Cities" strategy [1] - The focus will be on leveraging scale, network, and service advantages to enhance acquisitions and strategic partnerships in medical devices, retail chains, and traditional Chinese medicine [1] Group 3: Industry Trends and Digital Transformation - The company is positioned fifth in the pharmaceutical distribution industry, with ongoing reforms in bulk purchasing and regional centralized procurement accelerating industry consolidation [2] - Significant investments in digital infrastructure include the development of various management systems and an e-commerce platform, enhancing operational efficiency and customer service [2] Group 4: Logistics and Supply Chain Development - The company operates leading modern pharmaceutical logistics centers, with distribution centers established in 25 provinces and over 810 compliant delivery vehicles [2] - Collaborations with major logistics partners ensure nationwide pharmaceutical logistics service capabilities [2]

证券代码:000950 证券简称:重药控股 重药控股股份有限公司投资者关系活动记录表 编号:2023-013 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □其他 (请文字说明其他活动内容) 参与单位: 国金证券、东北证券、恒健远志投资、兴银理财、中睿合银、 博行资本、招银理财 活动参与人员 上市公司接待人员: 总经理 刘伟 财务总监、董事会秘书 邱天 证券事务代表代表 曹芳 时间 2023 年 9 月 15 日 地点 公司会议室 形式 现场会议 1、公司器械业务近几年来增长较快,后续对器械的规划 和预期是什么样的? 今年计划器械板块实现营收 120 亿,十四五规划是做到 交流内容及具体 200 亿,根据现阶段发展来看,有望进一步提升。目前国外市 问答记录 场药品与器械的占比约为 1:1,而国内市场较为分散,器械占 比很低。今年上半年,公司器械业务收入占比为 16.37%,下 属子公司也在大力扩展器械业务,逐步提高器械板块的收入占 比。同时,公司成立了器械事业部,通过专营器械和药品器械 1 兼营两种模式进行虚实线双线管理,推动搭建器械细分市场 ...

证券代码:000950 证券简称:重药控股 重药控股股份有限公司投资者关系活动记录表 编号:2023-012 | --- | --- | --- | |----------------|-------------------------------|--------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | (请文字说明其他活动内容) | | | 参与单位:泰康养老、西南证券 | | | 活动参与人员 | | | | | 上市公司接待人员:证券事务代表 | 曹芳 | | 时间 | 2023年9月4日 | | | 地点 | 公司会议室 | | | 形式 | 线上会议 | | 1、公司器械业务增长点是什么? 医疗器械类是公司第二大类经营产品,也是近两年来发展 较快的一路军。2023 年上半年,公司器械板块实现营业收入 66.67亿元,同比增长 65.66%,收入占比16.37%,毛利率12.1%, 公司在去年下半年及今年新 ...

重药控股股份有限公司 关于重庆化医控股集团财务有限公司的 风险持续评估报告 按照深交所《深圳证券交易所上市公司信息披露指引第 7 号——交易与关 联交易》的要求，由于公司与重庆化医控股集团财务有限公司（以下简称"财务 公司"）存在持续关联交易，需定期对财务公司与财务报表相关的资金、信贷、 投资、稽核、信息管理等风险管理体系的制定及实施情况进行评估。具体情况 报告如下： 一、财务公司基本情况 财务公司是经原中国银行业监督管理委员会（银监复[2010]589 号）文件批 准成立的非银行金融机构，2010 年 12 月 15 日取得《金融许可证》（机构编码： L0119H250000001）。公司成立于 2010 年 12 月 22 日，已办理完三证合一，统 一社会信用代码：915000005656440067；公司法定代表人：曾中全；注册及营 业地：重庆市北部新区高新园星光大道 70 号天王星 A1 座 2 楼。 财务公司经营范围：对成员单位办理财务和融资顾问、信用鉴证及相关的 咨询、代理业务；协助成员单位实现交易款项的收付；经批准的保险代理业务； 对成员单位提供担保；办理成员单位之间的委托贷款及委托投资；对成员 ...

Revenue and Financial Performance - The company achieved a revenue of 40.715 billion yuan in the first half of 2023, representing a year-on-year increase of 24.61%[132] - The total profit amounted to 756 million yuan, up 24.74% compared to the previous year, while the net profit attributable to shareholders reached 514 million yuan, growing by 28.10%[132] - The pure sales channel generated 31.266 billion yuan, accounting for 76.79% of total revenue, with a year-on-year increase of 22.21%[133] - The distribution channel saw a revenue of 7.766 billion yuan, which is 19.07% of total revenue, marking a significant growth of 33.90%[133] - The retail segment reported a revenue of 1.549 billion yuan, contributing 3.80% to total revenue, with a growth rate of 26.66%[133] - The pharmaceutical segment generated 33.123 billion yuan in revenue, a year-on-year increase of 17.89%, representing over 80% of total sales[138] - The medical device segment achieved a revenue of 6.667 billion yuan, growing by 65.66% and accounting for 16.37% of total revenue[139] - The company's operating revenue for the reporting period reached ¥40.72 billion, an increase of 24.61% compared to ¥32.67 billion in the same period last year[151] - Net profit attributable to shareholders was ¥513.66 million, reflecting a growth of 28.10% from ¥400.97 million year-on-year[151] - The total assets at the end of the reporting period amounted to ¥63.99 billion, an increase of 11.89% from ¥57.19 billion at the end of the previous year[151] Investment and Acquisitions - Investment income from pharmaceutical industrial investments amounted to approximately 140 million yuan during the reporting period[6] - The company has engaged in multiple mergers and acquisitions to strengthen its medical device distribution market, including the establishment of new subsidiaries[22] - The company completed acquisitions totaling ¥207,608,780.00, enhancing its market presence in the pharmaceutical distribution sector[187] - The company has a significant investment strategy through a controlled fund, holding a 99.8% stake and having veto power over investment decisions[24] - The company has invested in a medical device company in Chongqing that produces AEDs, becoming the first domestic AED manufacturer in Western China, and has also invested in a company developing safety blood collection and infusion needles[199] Cash Flow and Financial Management - The net cash flow from investment activities was -129.46 million yuan, reflecting an increase in cash outflow due to higher acquisition payments compared to the previous period[12] - The net increase in cash and cash equivalents was -810.45 million yuan, indicating a slight decrease compared to the previous period[12] - The company's cash flow from operating activities was negative at -¥3.82 billion, a decline of 27.45% compared to -¥2.99 billion in the previous year[151] - The company reported a maximum daily deposit limit of 99 million yuan with a financial affiliate, with a current balance of approximately 96.69 million yuan[80] - The financial company controlled by the group has a loan limit of 100 million yuan, with a current balance of 1.8 million yuan[61] Accounts Receivable and Risk Management - The accounts receivable balance increased to 36.64 billion yuan, representing 57.25% of total assets, due to rapid revenue growth and delayed collection[14] - The company emphasizes risk management for accounts receivable, particularly for clients outside public medical institutions[26] Market Expansion and Presence - The company has expanded its national presence with over 220 subsidiaries across 30 provinces, municipalities, and autonomous regions in China[7] - The company expanded its market presence by adding 9 new cities, enhancing its drug and medical device distribution capabilities[135] - The company operates 923 retail stores, an increase of 117 stores from the previous year, with a notable growth in DTP prescription drug sales by 39%[136] - The logistics and distribution network includes over 810 vehicles and 25 provincial distribution centers, enhancing supply chain capabilities[141] - The company has established a third-party logistics system, with over 20 subsidiaries holding third-party storage qualifications, generating approximately 25 million yuan in third-party storage revenue during the reporting period[197] Social Responsibility and Compliance - The company reported a significant focus on social responsibility, aiming to provide high-quality services and contribute to human health, with a vision to become a leading pharmaceutical health industry group in China[54] - The company has established a social responsibility leadership group, led by the chairman, to oversee social responsibility decisions and initiatives[54] - The company has actively participated in rural revitalization efforts through consumption poverty alleviation and issuing rural revitalization notes[55] - The company has maintained a commitment to ensuring the supply of essential medicines and medical supplies in response to national requirements[72] - The company has not experienced any major litigation or arbitration matters during the reporting period[57] - The company has not faced any administrative penalties related to environmental issues during the reporting period[54] - The company has not engaged in any significant related party transactions during the reporting period[77] - The company has not reported any non-operating related party debt transactions during the reporting period[85] Fundraising and Financial Strategy - The total amount raised in 2023 through public offerings was CNY 20,000 million, with all funds fully utilized[18] - The company has not changed the purpose of the raised funds, maintaining a 0.00% change in usage ratio[18] - The company has not reported any changes in the use of raised funds during the reporting period[19] - The company plans not to distribute cash dividends or issue bonus shares for the current fiscal year[101]